Clinical trial · Observational
Using a Population Pharmacokinetic Model to Estimate the Dosage of Teicoplanin in Patients With Hematologic Malignancy or Critical Illness
National Taiwan University Hospital Yun_Lin Branch
NCT06674330CI-TRIAL-00082251not yet recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Model Informed Precision Dosing (MIPD) integrates clinical data to optimize dosing for patients with unstable pharmacokinetics, like those with hematologic malignancies or critical illnesses. This study aims to create a pharmacokinetic model for teicoplanin, addressing complex dosing challenges and improving therapeutic outcomes through MIPD-driven recommendations.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Critical Illness | — | UNRESOLVED | — |
| Hematological Malignancies | Hematopoietic and Lymphoid Cell Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| concentration of teicoplanin | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- use population pharmacokinetics model to find out the risk factors
- timeFrame
- From enrollment to the end of treatment at last 2 weeks
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
Show eligibility criteria text
Inclusion Criteria: * Adult patients aged over 20 diagnosed with hematologic malignancy or critical illness. * Clinically require teicoplanin for treating fever with suspected Gram-positive bacterial infection for more than 48 hours. Exclusion Criteria: * Adult patients without hematologic malignancy or critical illness. * Patients not using teicoplanin for fever with suspected Gram-positive bacterial infection. * patients receiving renal dialysis within 48 hours of starting teicoplanin. * Patients treated with teicoplanin for less than 48 hours. * Pregnant women.
References
Publications (0)
Data not yet available
No reference posted for this study.